Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved ejection fraction (HFpEF)].
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Medical history of heart failure (HF) with:
Left ventricular ejection fraction (LVEF) >40%.
End-diastolic interventricular septal wall thickness (IVST) ≥12 mm.
Willing and able to undergo scintigraphy.
Exclusion criteria
Diagnosis of heart failure with reduced ejection fraction (HFrEF) (EF ≤40%).
Prior clinical history of myocardial infarction, CABG or multi-vessel obstructive coronary disease (>50% stenosis of ≥2 epicardial coronary arteries).
Presence or history of any severe valvular heart disease (obstructive or regurgitant).
A confirmed diagnosis of a non-amyloid infiltrative cardiomyopathy (ie, cardiac sarcoidosis, hemochromatosis), muscular dystrophies, cardiomyopathy with reversible causes, hypertrophic obstructive cardiomyopathy with known genetic etiology, or known pericardial constriction.
Any type of diagnosed amyloidosis (eg, amyloid A amyloidosis, primary [light chain] amyloidosis) or prior diagnosis of ATTR-CM.
Primary purpose
Allocation
Interventional model
Masking
347 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal